DÄ internationalArchive34-35/2007Conservative Treatment of Benign Prostatic Hyperplasia

Review article

Conservative Treatment of Benign Prostatic Hyperplasia

Dtsch Arztebl 2007; 104(34-35): A-2354

Michel, M C; Berges, R; Dreikorn, K; Madersbacher, S; Muschter, R

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Berges R, Dreikorn K, Höfner K et al.: Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS). Urologe A 2003; 42: 584–90. MEDLINE
2. Emberton M, Andriole GL, de la Rosette JJMCH et al.: Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267–73. MEDLINE
3. Jimenez-Cruz F: Identifying the patients at risk for disease progression. Eur Urol Suppl 2003; 2: 6–12.
4. Berges R, Dreikorn K, Höfner K et al.: Leitlinien der Deutschen Urologen zur Therapie des benignen Prostatasyndroms. Urologe A 2003; 42: 722–38. MEDLINE
5. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH: EAU 2004 Guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH Guidelines). Eur Urol 2004; 46: 547–54. MEDLINE
6. Michel MC, Vrydag W: a1-, a2- and b-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147: S88–119. MEDLINE
7. McConnell JD, Roehrborn CG, Bautista O et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–98. MEDLINE
8. Narayan P, Evans CP, Moon T: Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003; 170: 498–502. MEDLINE
9. Djavan B, Chapple C, Milani S, Marberger M: State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081–8. MEDLINE
10. Berges RR, Michel MC, Jonas U: a1-Rezeptorenblockade zur Therapie des BPH-Syndroms. Richtige Dosierung für optimale Wirkung. Urologe A 2002; 41: 452–7. MEDLINE
11. Barendrecht MM, Koopmans RP, de la Rosette JJMCH, Michel MC: Treatment for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 2005; 95 (Suppl. 4): 19–28. MEDLINE
12. van Dijk MM, de la Rosette JJ, Michel MC: Effects of a1-adrenergic receptor antagonists on male sexual function. Drugs 2006; 66: 287–301. MEDLINE
13. Andriole G, Bruchovsky N, Chung LWK et al.: Dihydrotestosterone and the prostate: the scientific rationale for 5a-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399–403. MEDLINE
14. Boyle P, Gould AL, Roehrborn CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405. MEDLINE
15. McConnell JD, Bruskewitz R, Walsh P et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557–63. MEDLINE
16. Edwards JE, Moore RA: Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urology 2002; 2: 14. MEDLINE
17. Evans HC, Goa KL: Dutasteride. Drugs Aging 2003; 20: 905–16. MEDLINE
18. Lepor H, Williford WO, Barry MJ et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533–9. MEDLINE
19. Debruyne FM, Jardin A, Colloi D et al.: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34: 169–75. MEDLINE
20. Kirby R, Roehrborn CG, Boyle P et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119–26. MEDLINE
21. Bent S, Kane C, Shinohara K et al.: Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557–66. MEDLINE
22. Herbison P, Hay-Smith J, Ellis G, Moore K: Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841–4. MEDLINE
23. Abrams P, Kaplan S, de Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999–1004. MEDLINE
24.Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817–20. MEDLINE

Info

Specialities